ArticleFrontiers in bioengineering and biotechnology2026
Reperfused human umbilical cords: hydrodynamic and hemolytic analysis of the
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A new type of umbilical vascular access routes is needed for the extracorporeal blood circuits, which are part of artificial placenta treatment. So far, devices and techniques for this purpose have been developed and tested only in large animal models or simulators. We have previously reported a test setup for the development and training of umbilical vessel cannulation on reperfused human umbilical cords. It allows the simulation of the insertion of large-bore cannulae into the perfused umbilical arteries and vein, as it is planned to be performed in an ex utero intra partum procedure. We present an evolved version of the test stand with reduced priming volume, resistance and hemolysis. Methods: Standardization and optimization of cannulae and tubing reduced flow resistance and priming volume. Hematocrit was adjusted to 0.3. Fourteen umbilical cords were harvested, prepared, visually analyzed, and used to validate the setup. Seven circuits were primed with autologous placental blood at a hematocrit of 30%, and seven were primed with saline solution. A volume flow of 70 mL/min was targeted, and pressures and hemolysis were measured. Results: Differences in vessel structure and coiling were identified. The measured pressure drops were in a physiological range. There was no significant hemolysis caused by the cannulas or the umbilical cord compared to the tubing, reservoir, and blood pump. Conclusion: The test stand for reperfused human umbilical cord specimens primed with autologous placental blood or saline solution can provide a biosimilar model for medical therapies with low ethical concerns and patient risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.